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Summary 
The proficiency study for macrolides in porcine tissue was organized in accordance with ISO/IEC 
Guide 43-1 and 43-2 and ILAC-G13, and under accreditation (Dutch Accreditation Board, ILAC-G13).  
 
For this proficiency study, four test materials were prepared: 
• A blank porcine muscle material; 
• A porcine muscle material containing about 80 µg/kg tylosin, 300 µg/kg josamycin, 100 µg/kg 
lincomycin and 150 µg/kg tulathromycin (spiked); 
• A blank porcine kidney material; 
• A porcine kidney material containing about 80 µg/kg tylosin, 300 µg/kg josamycin and 50 µg/kg 
tilmicosin (spiked). 
During homogeneity testing, all materials proved to be sufficient homogenous for proficiency testing. 
The stability test demonstrated that no significant loss of any of the compounds occurred during the 
timescale of the proficiency test. 
 
Thirteen laboratories subscribed for participation in the proficiency study. Eleven laboratories managed 
to submit valid results within the timeframe of the stability study. For muscle, seven and for kidney 
three of the participating laboratories applied a validated method.   
 
Some false negatives and false positives occurred in this proficiency study.  Although spiramycin was 
not present in the samples, one laboratory found spiramycin in both of the kidney materials. The same 
laboratory missed tylosin in the muscle samples. Two laboratories did not detect tilmicosin in the 
sample, although this compound was included in their method. 
 
The laboratory's performance for the materials containing macrolides are summarized in Table 1.  
Table 1. Summary of the laboratory's performance of the materials containing macrolides 
Matrix Compound 
Assigned value 
(X) 
(µg/kg) 
Uncertainty of X 
(µg/kg) 
No. of labs 
that reported 
results 
No. of satisfactory 
results 
Tylosin 38.3 4.3 10 7 
Josamycin 197 41 8 6 
Lincomycin 120 11 8 8 
Muscle 
Tulathromycin 217 42 5 5 
Tylosin 66.7 11.5 10 8 
Josamycin 177 24 7 5 Kidney 
Tilmicosin 36.5 4.6 6 6 
 
For lincomycin, tulathromycin and tilmicosin all reported results were satisfactory. For tylosin and 
josamycin some questionable and unsatisfactory results are observed. The occurrence of questionable or 
unsatisfactory results could not be explained by the applied detection or sample preparation technique 
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nor by the use of different reference standards or the fact that some laboratories reported tylosin A and 
some reported the total amount of tylosin. 
 
In this proficiency study 45% of the laboratories showed acceptable performance in terms of accuracy 
and the absence of false positive and false negative findings. 
 
Based on the results of this proficiency study it is concluded that: 
• Although regulations for most macrolides are established before 2005, many laboratories do not 
have a validated and accreditated method for the analysis of all relevant macrolides.  
• For tylosin and josamycin more effort is needed for an accurate and more precise quantification of 
macrolides in porcine muscle. The elimination of ion suppression and the use of a well 
characterized tylosin reference standard could be important issues. 
• In general, more effort is needed to control food safety with respect to the occurrence of macrolide 
residues. 
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1 Introduction 
1.1 Proficiency testing 
Proficiency testing is conducted to provide laboratories with a powerful tool to evaluate and 
demonstrate the reliability of the data that is produced. Next to validation and accreditation, proficiency 
testing is an important requirement of the EU Additional Measures Directive 93/99/EEC [1] and is 
increasingly important in the new ISO 17025:2005 [2].  
No internationally focused broad range proficiency studies regarding the analysis of macrolides in 
porcine muscle or kidney that focused on the quantitative aspect were organized during the last years: 
an inter-laboratory quality control for this analyte-matix combination was lacking. Therefore, RIKILT 
decided to organize a proficiency study regarding this subject.  
 
The aim of this proficiency study was to give laboratories the possibility to evaluate or demonstrate 
their competence for the analysis of macrolides in porcine tissues. Two different tissues were included 
in the proficiency study giving the opportunity to compare method performances for both matrices.  
This study also provided an evaluation of the methods applied for quantitative and confirmatory 
analysis of macrolides in porcine tissue.  
 
This proficiency study was conducted in accordance with guidelines ISO/IEC 43-1 [3], ISO/IEC 43-2 
[4] and ILAC-G13 [5] and was organized under accreditation by RIKILT - Institute of Food Safety. 
1.2 Macrolides 
The macrolides are antimicrobial agents consisting of one or more deoxy sugars bound to a 14, 15 or 
16-membered macrocyclic ring. The first macrolide, erythromycin, was isolated in 1952 from 
Streptomyces erythreus [6].  
 
Macrolides have a very broad clinical application in livestock, poultry and domestic animals in the 
treatment of infections such as respiratory tract and soft tissue infections, being more effective towards 
Gram-positive than Gram-negative bacteria. The mechanism of action of the macrolides is inhibition of 
bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby 
blocking translocation of peptidyl tRNA [6] or causing dissociation of the peptidyl-tRNA [7]. Tylosin 
and lincomycin are the most commonly used macrolides for controlling dysentery and Mycoplasma 
infections in swine [7].  
 
Macrolide resistance is an emerging problem [8]. Especially because macrolides have been used in the 
treatment of food producing animals for decades [7], control of food products for the presence of 
macrolide residues is of importance.  
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The use of macrolides as veterinary drug is regulated within the European Union. Macrolides are 
included in Annex I: pharmacologically active veterinary products for which a Maximum Residue Limit 
(MRL) is established [10]. Regarding macrolides MRLs for several species and tissues are established.  
 
This proficiency study focused on tylosin, lincomycin (a lincosamide, closely related to macrolides), 
josamycin, tilmicosin and tulathromycin in porcine muscle and kidney. The MRLs for these compounds 
in porcine muscle and kidney are presented in Table 1.  
Table 2. MRL in porcone muscle and kidney of macrolides included in the inter-laboratory study 
Compound MRL in porcine muscle (µg/kg) 
MRL in porcine kidney 
(µg/kg) Reference 
Tylosin 100 100 [10] 
Lincomycin 100 1500 [10] 
josamycin 200 400 [11] 
Tilmicosin 50 100 [10] 
tulathromycin - 3000 [12] 
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2 Test materials 
2.1 Sample preparation 
For muscle one blank material and one material containing tylosin (TYL), josamycin (JMC), lincomycin 
(LMC) and tulathromycin (TMC) were prepared. For kidney one blank material and one material 
containing tylosin,  josamycin and tilmicosin (TMS) were prepared. The macrolide containing materials 
were prepared by adding methanolic solutions of these compounds to blank materials. The materials 
presented in Table 2 were obtained. Each of the materials was homogenised under cryogenic conditions 
according to in-house standard operating procedures. 
Table 3.Target amount of macrolides in the inter-laboratory study test materials  
Target amount (µg/kg)  
Material code 
TYL JMC LMC TMC TMS 
M-A - - - - - 
M-B 80 300 100 130  
K-A - - - - - 
K-B 90 300 - - 45 
2.2 Sample identification 
The materials were stored in polypropylene containers containing at least 25 gram of sample, yielding a 
total of 38 containers of material M-A and K-A, 80 containers of material M-B and 60 containers of 
material K-B. The muscle samples were randomly coded with a code from 
MACRO/2008/MUSCLE/001 through 118. The kidney samples were randomly coded with a code from 
MACRO/2008/KIDNEY/001 through 098. 
 
For homogeneity and stability testing, 20 randomly selected containers of material M-B and K-B were 
assigned. For each laboratory a sample set was prepared consisting of one randomly selected sample of 
material M-A, K-A and K-B and two randomly selected samples of material K-B. The codes of the 
samples belonging to each sample set are presented in Annex 1. 
2.3 Homogeneity study 
The homogeneity of the materials was tested according to The International Harmonized Protocol for 
Proficiency Testing of Analytical Laboratories [13] and ISO/DIS 13528 [14], taking into account the 
insights discussed by Thompson [15] regarding the Horwitz equation.  
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With this procedure the between-sample standard deviation ( ss ) is compared with the target  standard 
deviation derived from the Horwitz equation ( Hσ , §4.3). A material is considered adequately 
homogeneous if Hs σ3.0s ≤ . 
 
Ten containers of materials M-B and K-B were each analyzed in duplicate for TYL, JMC, LMC, TMC, 
TMS, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and valnemulin to 
determine the homogeneity of the materials. The results of the homogeneity study and their statistical 
evaluation are presented in Annex 2a through f. For TMC no data were obtained during the 
homogeneity study. Because all materials demonstrated to be sufficiently homogeneous for use in the 
proficiency study for TYL, JMC, LMC and TMS it was concluded that also TMC was sufficiently 
homogeneous. The amounts determined during the homogeneity study are presented in table 3. 
 
No extensive homogeneity study was carried out for materials M-A and K-A. The homogeneity of these 
materials is not relevant because the results of these materials will not be evaluated in a quantitative 
way. Furthermore, it is assumed that the homogeneity of material M-A and K-A are comparable with 
the homogeneity of the other materials because all materials are homogenized in the same way. 
Nevertheless, three randomly selected samples of material M-A and K-A were analyzed for 12 
macrolides. No aivlosin, erythromycin, gamithromycin, JMC, LMC, pirlimycin, tiamulin, TMS, TMC, 
TYL, spiramycin or valnemulin was detected. It was concluded that materials M-A and K-A are suited 
to use as blank materials in the proficiency study. 
Table 4. Determined amount of macrolides in the proficiency study test materials 
Material code Amount of TYL (µg/kg) 
Amount of 
JMC (µg/kg) 
Amount of LMC 
(µg/kg) 
Amount of TMS 
(µg/kg) 
M-A - - - - 
M-B 52.6 245 145 - 
K-A - - - - 
K-B 68.4 242 - 30.9 
2.4 Participants 
Thirteen laboratories subscribed for participation in the proficiency study macrolides in porcine tissue. 
Most participating laboratories are situated in Europe.  
2.5 Sample distribution 
Each of the participating laboratories received a randomly assigned laboratory code (1 through 13). The 
sample sets with the corresponding number, consisting of five coded samples (Annex 1) were sent to the 
participating laboratories during the first half of August 2008. The sample sets were packed in an 
insulating box containing dry ice or cool packs and were dispatched to the participants immediately by 
courier. Three laboratories reported that the samples were not sufficiently frozen at arrival. A new 
 RIKILT Report 2009.003 11
sample set was sent to each of these laboratories. For one sample set a severe delay at customs occurred. 
Therefore the corresponding laboratory was not able to analyze the samples within the time frame of the 
study. All other laboratories confirmed the receipt of the samples in good condition (frozen). The 
samples were accompanied by a letter (Annex 3) describing the requested analyses, an 
acknowledgement of receipt form and a results form.  
 
The laboratories were asked to store the samples until analysis according to their own laboratory’s 
procedure. A duplicate analysis of each sample was requested, resulting in two results for materials M-
A, K-A and K-B, and four results for material M-B. The deadline for sending in results was October 17th 
2007, allowing the participants at least six weeks for analysis. 
2.6 Stability 
Just after preparation of the materials three randomly selected samples of each material were stored at 
<-70 °C. It is assumed that the macrolides in the samples are stable at these storage conditions. The 
remaining samples were stored at -20 °C. On November 10th three randomly selected samples of each 
material were moved from -20 °C to room temperature to thaw. On November 20th, after the deadline 
of the inter-laboratory study, the samples stored at <-70 °C, three randomly selected samples of each of 
the materials stored at -20°C and the thawed samples were analyzed. For each set of samples, the 
average of the results and the standard deviation was calculated.  
 
First it was determined if a consequential instability occurred [13, 14]. A consequential instability 
occurs when the average value of the samples stored at -20°C is more than 0.3σH below the average 
value of the samples stored at <-70 °C. If so, the instability has a significant influence on the calculated 
z-scores. Second, it was determined if a statistically significant instability occurred using a Students t-
test [14]. The hypothesis for this test is: 
 
)x(E)x(E d0 =  
  
where:   
E( 0x ) = the expected amount of macrolides for the samples stored at <-70 °C;  
E( dx ) = the expected amount of macrolides for the samples stored at -20 °C. 
 
The value t is calculated by: 
 
d0
d0
n
1
n
1
s
xx
t
+
-
=  
 
where:  
0x = the average amount calculated for the samples stored at <-70 °C; 
dx = the average amount calculated for the samples stored at 20 °C; 
s = pooled standard deviation; 
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0n = number of results of the samples stored at <-70 °C; 
dn = number of results of the samples stored at 20 °C; 
 
The calculated value t is compared to a critical value (tcrit) derived from a Students-t table with t having 
2nn d0 -+  degrees of freedom [14]. If t < tcrit it is demonstrated that no statistically significant 
difference between the average amount of the samples at both storage conditions is found.  
 
The results and statistical evaluation of the stability test are presented in Annex 4. For tulathromycin a 
severe variation in the replicate results was obtained and therefore evaluation of the stability is not 
possible for this compound. For the other compounds in all materials no statistically significant 
instability was observed when the samples are stored at -20 °C. For josamycin in muscle a severe 
increase in the standard deviation of the results is observed after 92 days of storage at -20°C. Using an F 
test it was shown that the difference between the standard deviation of the results of storage at <-70°C 
and -20°C is significant. Therefore the t test is not a valid test for comparing both of the averages for 
josamycin in muscle.  
  
When looking at the absolute difference between the averages at both storage conditions a consequential 
instability was only observed for josamycin in muscle. Therefore, the evaluation of  laboratories that 
obtained a z-score just outside the 2s or 3s limits for josamycin in muscle should not be used for 
evaluation purposes but for information only. For tulathromycin in muscle no conclusions regarding the 
quantitative aspect can be drawn from the results.  
 
For all analytes in the thawed samples a severe decrease of the level was observed ranging from a loss 
of 32% for josamycin in muscle to 74% for tylosin in muscle. This indicates that if the samples arrived 
thawed, no conclusions can be drawn from this proficiency study.  
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3 Applied methods of chemical analysis 
The participating laboratories applied different sample preparation procedures for the analysis of 
macrolides in porcine tissues. All laboratories apply the same method for muscle as for kidney, with the 
exception of lab 7. Lab 7 added an additional extraction using hexane to remove fat. A schematic 
overview of the methods applied is presented in Annex 5. 
 
For the analysis of macrolides in porcine tissue many different extraction solvents or mixtures of 
solvents were used at various pH's. Four laboratories apply an aqueous buffer for extraction. Three of 
them apply a pH of 4.0, the other a pH of 10.5. Three laboratories use only acetonirile as the extraction 
solvent. A phase exchange or dilution with water is needed to make the extract suitable for analysis. 
 
For the sample clean up also several different techniques were applied. Five laboratories applied solid 
phase extraction using either the reversed phase or ion exchange principle. Three laboratories only 
diluted and/or filtrated the raw extract before analysis. 
 
Two detection techniques were applied for the quantitative analysis of macrolides in porcine tissues. 
One laboratory applied LC combined with photo diode array detection (PDA). The other eight labs used 
MS/MS as the detection techniques. This detection technique is suited for confirmation of the identity of 
group B substances according to 2002/657/EC [17].  
 
Of the participants that used LC-MS/MS as a detection technique, six used one or more internal 
standards for the quantification of the macrolides. The internal standards used are: 
• roxithromycin 
• clindamycin 
• oleandomycin 
• erythromycin-13C-d3 
 
The laboratories that did not analyze for one or more of the macrolides mentioned in the invitation letter 
are presented in Table 4. It is noted that especially aivlosin, gamithromycin, tiamulin and tulathromycin 
are not included by most laboratories. This is not very surprising, because no regulations are set for 
gamithromycin and for aivlosin and tulathromcin regulations are only established in 2007 [16] and 2004 
[12] respectively. For tiamulin regulations were established in 1999 [17] but tiamulin is considered a 
pleuromutilin instead of a macrolide. Nevertheless it has a structural relation with macrolides. 
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Table 5. Overview of laboratories that did not include all macrolides in the analysis. 
Compound Not included by lab 
Aivlosin 1, 2, 3, 5, 7, 8, 12 
Erythromycin 3, 9 
Gamythromycin 1, 2, 3, 5, 7, 8, 9, 12, 13 
Josamycin 3, 9 
Lincomycin 3, 8, 9 
Pirlimycin 2,3,7 
Tiamulin 1, 2, 3, 8, 9, 12 
Tilmicosin 3, 9 
Tulathromycin 2, 3, 7, 8, 9, 12 
Tylosin  
Spiramycin 3, 8 
Valnemulin 2,3,7,8,9,12 
 
An overview of the method performance characteristics of the participating laboratories is presented in 
Annex 6. All values are presented as reported by the laboratories without any adjustments. Seven of the 
eleven laboratories that submitted results reported to have applied a validated method for the analysis of 
muscle. Of these laboratories five have an accreditation for this method. For the analysis of kidney only 
three laboratories reported to have applied a validated method. 
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4 Statistical evaluation 
The statistical evaluation was carried out according to the International Harmonized Protocol for the 
Proficiency Testing of Analytical Laboratories [13], elaborated by ISO, IUPAC and AOAC and 
ISO/DIS 13528 [14] in combination with the insights published by the Analytical Methods Committee 
[21, 22] regarding robust statistics. 
4.1 Calculation of the assigned value 
The assigned value (X) was determined using robust statistics [14,20,21]. The advantage of robust 
statistics is that all values are taken into account: outlying observations are retained, but given less 
weight. Furthermore, it is not expected to receive normally distributed data in a proficiency test. When 
using robust statistics, the data does not have to be normally distributed in contrast to conventional 
outlier elimination methods. 
The robust mean of the reported results of all participants, calculated from an iterative process that starts 
at the median of the reported results using a cut-off value depending on the number of results, was used 
as the assigned value [14,20]. The assigned value is therefore a consensus value. 
4.2 Calculation of the uncertainty of the assigned value 
The uncertainty of the assigned value is calculated to determine the influence of this uncertainty on the 
evaluation of the laboratories. A high uncertainty of the assigned value will lead to a high uncertainty of 
the calculated participants za-scores. If the uncertainty of the assigned value and thus the uncertainty of 
the za-score is high, the evaluation could indicate unsatisfactory method performance without any cause 
within the laboratory. In other words, illegitimate conclusions could be drawn regarding the 
performance of the participating laboratories from the calculated za-scores if the uncertainty of the 
assigned value is not taken into account. 
The uncertainty of the assigned value (the robust mean) is calculated from the estimate of the standard 
deviation of the assigned value and the number of values used for the calculation of the assigned value: 
 
n
σˆ
u =  
 
where: 
u = uncertainty of the assigned value;  
n = number of values used to calculate the assigned value;  
σˆ = The estimate of the standard deviation of the assigned value resulting from robust statistics. 
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According to ISO/DIS 13528 [14] the uncertainty of the assigned value (u) is negligible and therefore 
does not have to be included in the statistical evaluation if: 
 
pσ3,0u ≤  
 
where: 
u = The uncertainty of the assigned value; 
p
σ = target standard deviation (§ 4.3). 
 
In case the uncertainty of the assigned value does not comply with this criterion, the uncertainty of the 
assigned value should be taken into account when evaluating the performance of the participants 
regarding the accuracy (§ 4.4). 
4.3 Calculation of the target standard deviation 
According to Commission Decision 2002/657/EC [19], the coefficient of variation for the repeated 
analysis of a reference or fortified material under reproducibility conditions, shall not exceed the level 
calculated by the Horwitz equation. The Horwitz equation, 8495.0H c02.0σ = , presents a useful and 
widespread applied relation between the expected standard deviation under reproducibility conditions, 
Hσ and the concentration, c (g/g). It expresses inter-laboratory precision expected in inter-laboratory 
trials. Therefore, this relation is suitable for calculating the target standard deviation, pσ in proficiency 
studies. 
 
Thompson [13] demonstrated that the Horwitz equation is not applicable to the lower concentration 
range (<120 µg/kg) as well as to the higher concentration range (>138 g/kg). Therefore a 
complementary model is suggested: 
 
For analyte concentrations <120 µg/kg: 
c22.0σ H =  
 
For analyte concentrations >138 g/kg: 
5.0
H c01.0σ =  
 
where: 
Hσ = expected standard deviation in inter-laboratory trials; 
c  = concentration of the analyte (g/g). 
  
The target standard deviation ( pσ ) of tylosin and tilmicosin were determined using the equation for 
analyte concentrations <120 µg/kg. The target standard deviation ( pσ ) of josamycin, lincomycin and 
tulathromycin were determined using the Horwitz equation. In these calculations c = the assigned value 
(X) expressed in g/g and pH σσ = . 
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4.4 Performance characteristics with regard to the accuracy 
For illustrating the performance of the participating laboratories with regard to the accuracy a za-score is 
calculated. For the evaluation of the performance of the laboratories, the Guidelines of ISO/IEC Guide 
43-1 [3] and ISO/DIS 13528 [14] are applied. According to these guidelines za-scores are classified as 
presented in Table 5.  
 
Table 6: Classification of za-scores 
z ≤ 2 Satisfactory 
2 < z < 3 Questionable 
z ≥ 3 Unsatisfactory 
 
If the calculated uncertainty of the assigned value complies with the criterion mentioned in § 4.2, the 
uncertainty is negligible. In this case the accuracy z-score is calculated from: 
 
p
a σ
Xx
z
-
=  
 
where: 
az = accuracy z-score; 
x = the average result of the laboratory*; 
X = assigned value; 
pσ = target standard deviation. 
 
However, if the uncertainty of the assigned value does not comply with the criterion mentioned in § 4.2, 
it could influence the evaluation of the laboratories. Therefore in this case, the uncertainty is taken into 
account by calculating the accuracy z-score [14]: 
 
22
p
a
uσ
Xx
'z
+
-
=   
 
where: 
a'z = accuracy z-score taking into account the uncertainty of the assigned value; 
x = the average result of the laboratory*; 
X  = assigned value; 
pσ = target standard deviation; 
u  = uncertainty of the assigned value. 
                                                     
* In the evaluation x is an average of two or four values whereas pσ  is defined for a single analysis. This results 
in slightly optimistic z-scores. 
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5 Results and discussion 
Thirteen laboratories subscribed for the participation in the inter-laboratory study for macrolides in 
porcine tissue. Eleven laboratories managed to submit valid results for muscle and ten laboratories 
managed to submit valid results for kidney. Not all laboratories did include all macrolides present in the 
sample. The amount of laboratories submitting results for each macrolide present in the muscle and the 
kidney materials is presented in table 6. 
Table 7: Amount of laboratories that reported results for each macrolide in both muscle an kidney. 
Matrix Compound No. of labs that reported a result 
Tylosin 10 
Josamycin 8 
Lincomycin 8 
Muscle 
Tulathromycin 5 
Tylosin 10 
Josamycin 7 Kidney 
Tilmicosin 6 
 
For the materials for which less than seven laboratories reported quantitative results, the data is only 
evaluated for information. The assigned value and the z-scores are calculated, but no conclusions should 
be drawn from this regarding the performance of the laboratories. 
 
Some false negatives and false positives occurred in this proficiency study. An overview is given in 
Annex 7. Laboratory 4 and 8 did not detect tilmicosin in the kidney material (K-B) although tilmicosin 
is included in their method. It is noted that both labs did not yet validate their method for tilmicosin in 
kidney. Nevertheless, both finding are considered as false negatives. 
Laboratory 12 did not detect tylosin in the muscle samples (M-B) although tylosin was included in their 
validated method and their LoD was 3 µg/kg which is far below the level of tylosin present in the 
samples. This is considered to be a false negative result. Furthermore, this laboratory detected 
spiramycin in both kidney samples (K-A and K-B) at significant levels. These findings are considered to 
be false positive results. 
5.1 Evaluation of the results of tylosin 
Tylosin was present in both the muscle and the kidney material. All laboratories that reported results 
have tylosin included in their method. Laboratory 12 did not detect tylosin in the muscle samples. 
Therefore, the evaluation of tylosin in muscle and kidney are both based on ten results. The results for 
tylosin as well as the evaluation of it are presented in Annex 8.  
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For muscle the lowest value reported for tylosin is 24 µg/kg and the highest value is 76 µg/kg. The 
assigned value of tylosin in muscle is 38.3 µg/kg with an uncertainty of 4.3 µg/kg.  
The uncertainty of the assigned value of tylosin exceeds 0.3σp (§4.2). Therefore, for this material, the 
uncertainty of the assigned value is taken into account in the evaluation of the laboratories. The z'a-
scores for tylosin obtained by each laboratory were calculated. The results are presented in Appendix 
8a. Graphical representations of the z'a-scores are included. 
With respect to the accuracy the results of three laboratories (lab 2, 8 and 13) are questionable. The 
difference in accuracy among laboratories could not be attributed to differences in the applied sample 
preparation or detection technique. 
 
For kidney the lowest value reported for tylosin is 23 µg/kg and the highest value is 128 µg/kg. The 
assigned value of tylosin in muscle is 66.7 µg/kg with an uncertainty of 11.5 µg/kg. The uncertainty of 
the assigned value of tylosin exceeds 0.3σp (§4.2). Therefore, for this material, the uncertainty of the 
assigned value is taken into account in the evaluation of the laboratories. The z'a-scores for tylosin 
obtained by each laboratory were calculated. The results are presented in Appendix 8b. Graphical 
representations of the z'a-scores are included. With respect to the accuracy the results of laboratory 9 and 
12 are questionable. It is noted that both laboratories only filtered or diluted their raw kidney extract 
before analysis. The same accounts for laboratory 7, but they applied an additional hexane extraction. It 
might be possible that due to the limited sample clean up procedure, ion suppression results in an 
enhanced signal.  
 
The spreading in the reported results could be caused by the use of different reference standards or a 
different way of reporting results. According to regulations [10] the marker for tylosin is tylosin A. 
Therefore, laboratories should determine and report the amount of tylosin A solely. In table 7 the 
reference standard used by each of the laboratories are reported including whether the laboratory 
reported tylosin A or the total amount of tylosin. Of all of the used reference standards the  
certificates only indicate the purity of the total amount of tylosin. No specific information is given on 
the purity of tylosin A. Therefore, when determining the amount of tylosin A in an unknown sample, an 
extra error is introduced due to the unknown amount of tylosin A in the reference standard. This is an 
important complicating factor in the control of tylosin. 
Table 8: Overview of the used reference standards for tylosin and the way of reporting 
Lab code Manufacturer Catalogue number Lot Tylosin A / total z' -scores muscle 
1 Sigma T6134 108H1073 Total -1,04 
2 Sigma T6134 086K2004 Total 2,06 
3 Sigma   Total -0,56 
4 Sigma T6134 047K1639 Tylosin A -0,93 
5     -1,34 
6 Fluka 93806 1304363 Tylosin A -0,06 
7 Riedel de Haen 33864 7045X Tylosin A -1,36 
8 Sigma T6134 108H1073 Tylosin A 2,16 
9 Fluka 93806 1304363 Tylosin A 0,47 
12 Riedel de Haen 33847 7190X Tylosin A 2,55 
13     -1,04 
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In some cases laboratories used the same reference standard (even the same lot number), but no 
correlation was found between the z'a-scores and the reference standard used. Surprisingly, there is also 
no corrolation between the z'a-scores and whether laboratories reported the amount of tylosin A or the 
total amount of tylosin. 
 
Comparing the reported results for tylosin of the muscle and the kidney samples it is clear that both 
matrices result in a severe spreading of the laboratory results. No significant difference in the 
uncertainty of the assigned values for both matrices was demonstrated using the F-test.  
 When comparing results for muscle and kidney within a laboratory, it is expected that if a 
laboratory reports a deviating value for muscle, the value for kidney will deviate as well. Surprisingly, 
no correlation was found between the reported results for muscle and kidney for most laboratories. Only 
laboratory 3, 7 and 8 obtained comparable z'a-scores for muscle and kidney. 
5.2 Evaluation of the results of josamycin 
Josamycin was present in both the muscle and the kidney material. Josamycin was not included in the 
method by laboratories 3 and 9. No false negatives or false positives for josamycin occurred. Therefore, 
the evaluation of josamycin in muscle and kidney is based on eight and seven results respectively. The 
results for josamycin as well as the evaluation of it are presented in Annex 9.  
 
For muscle the lowest value reported for josamycin is 74.6 µg/kg and the highest value is 524 µg/kg. 
The assigned value of josamycin in muscle is 196.6 µg/kg with an uncertainty of 40.8 µg/kg.  
The uncertainty of the assigned value of josamycin exceeds σp. Therefore, for this material, the 
uncertainty of the assigned value is taken into account in the evaluation of the laboratories. The z'a-
scores for josamycin obtained by each laboratory were calculated. The results are presented in Appendix 
9a. Graphical representations of the z'a-scores are included. With respect to the accuracy the results of 
laboratories 8 and 13 are questionable. Laboratory 12 obtained a z'a-score just below -2: an 
unsatisfactory result. However, due to the consequential instability observed for josamycin in muscle, 
this result is not suited for evaluation purposes. The difference in accuracy among laboratories could not 
be attributed to differences in the applied sample preparation or detection technique. 
 
For kidney the lowest value reported for josamycin is 121 µg/kg and the highest value is 441 µg/kg. The 
assigned value of josamycin in muscle is 176.5 µg/kg with an uncertainty of 24.4 µg/kg. The 
uncertainty of the assigned value of josamycin exceeds 0.3σp (§4.2). Therefore, for this material, the 
uncertainty of the assigned value is taken into account in the evaluation of the laboratories. The z'a-
scores for josamycin obtained by each laboratory were calculated. The results are presented in Appendix 
9b. Graphical representations of the z'a-scores are included. With respect to the accuracy the results of 
laboratories 8 and 13 are questionable. The difference in accuracy among laboratories could not be 
attributed to differences in the applied sample preparation or detection technique. 
 
Comparing the results of the muscle and the kidney analysis for josamycin it is clear that both matrices 
result in a severe spreading of the results. No significant difference in the uncertainty of the assigned 
values for both matrices was demonstrated using the F-test. When comparing results for muscle and 
kidney within a laboratory, it is expected that if a laboratory reports a deviating value for muscle, the 
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value for kidney will deviate as well. Surprisingly, no correlation was found between the reported 
results for muscle and kidney for most laboratories. Only laboratory 7 and 8 obtained comparable z'a-
scores for muscle and kidney. 
5.3 Evaluation of the results of lincomycin 
Lincomycin was present only in the muscle material. Lincomycin was not included in the method by 
laboratory 3, 8 and 9. No false negatives or false positives for lincomycin occurred. Therefore, the 
evaluation of lincomycin in muscle is based on eight results. The results for lincomycin as well as the 
evaluation of it are presented in Annex 10.  
 
For lincomycin the lowest value reported is 68 µg/kg and the highest value is 208 µg/kg. The assigned 
value of lincomycin is 120.2 µg/kg with an uncertainty of 11.3 µg/kg. The uncertainty of the assigned 
value of lincomycin exceeds 0.3σp (§4.2). Therefore, the uncertainty of the assigned value is taken into 
account in the evaluation of the laboratories. The z'a-scores for lincomycin obtained by each laboratory 
were calculated. The results are presented in Appendix 10. A graphical representation of the z'a-scores is 
included. With respect to the accuracy all laboratories obtained satisfactory results.  
5.4 Evaluation of the results of tulathromycin 
Tulathromycin was present only in the muscle material. Tulathromycin was not included in the method 
by laboratory 2, 3, 7, 8, 9 and 12. No false negatives or false positives for tulathromycin occurred. 
Therefore, the evaluation of tulathromycin in muscle is based on five results. Because this number is 
below seven and because no stability information was obtained for tulathromycin, the evaluation of 
tulathromycin is for information only: no conclusions can be drawn regarding the performance of the 
laboratories. The results for tulathromycin as well as the evaluation of it are presented in Annex 11.  
 
For tulathromycin the lowest value reported is 105 µg/kg and the highest value is 408 µg/kg. The 
assigned value of tulathromycin is 217.2 µg/kg with an uncertainty of 42.5 µg/kg. The uncertainty of the 
assigned value of tulathromycin is about σp. Therefore, the uncertainty of the assigned value is taken 
into account in the evaluation of the laboratories. The z'a-scores for tulathromycin obtained by each 
laboratory were calculated. The results are presented in Appendix 11. A graphical representation of the 
z'a-scores is included. 
5.5 Evaluation of the results of tilmicosin 
Tilmicosin was present only in the kidney material. Tilmicosin was not included in the method by 
laboratory 3 and 9. Laboratory 1 only reported one result for tilmicosin. Laboratory 4 and 8 did not 
detect tilmicoin in the kidney sample, although tilmicosin was included in their method. Therefore, the 
evaluation of tilmicosin in kidney is based on six results. Because this number is below seven, the 
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evaluation is for information only: no clonclusions can be drawn regarding the performance of the 
laboratories. The results for tilmicosin as well as the evaluation of it are presented in Annex 12.  
 
For tilmicosin the lowest value reported is 22.8 µg/kg and the highest value is 83.7 µg/kg. The assigned 
value of tilmicosin is 36.5 µg/kg with an uncertainty of 4.6 µg/kg. The uncertainty of the assigned value 
of tilmicosin exceeds 0.3σp (§4.2). Therefore, the uncertainty of the assigned value is taken into account 
in the evaluation of the laboratories. The z'a-scores for tilmicosin obtained by each laboratory were 
calculated. The results are presented in Appendix 12. A graphical representation of the z'a-scores is 
included. 
5.6 Overall evaluation 
If not taking the results of tulathromycin in muscle and tilmicosin in kidney into account due to the low 
number of laboratories that reported results, from the 11 laboratories that submitted results 5 (i.e. 45%) 
showed optimal performance for the analysis of macrolides in muscle and kidney with respect to the 
accuracy and the occurrence of false positive and false negative results. An overview of the amount of 
satisfactory results is presented in table 8. A complete overview of z'a-scores is given in Annex 13. 
Table 9: Overview of the amount of satisfactory results for accuracy 
Matrix Compound No. laboratories that reported results 
No. of satisfactory 
results for accuracy 
No. of questionable 
results for accuracy 
No. of unsatisfactory 
results for accuracy 
Tylosin 10 8 2 0 
Josamycin 8 5 1 2 
Lincomycin 8 8 0 0 
Muscle 
Tulathromycin 5 5 0 0 
Tylosin 10 7 3 0 
Josamycin 7 5 1 1 Kidney 
Tilmicosin 6 6 0 0 
 
The amount of participating laboratories in the proficiency test for macrolides in porcine tissues is low. 
Many invited laboratories reported not to have a (validated) method available. Of the laboratories that 
did participate, many did not have all macrolides for which regulations are established included in their 
method.  
Furthermore a severe variation in the results is observed for all compounds. 
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6 Conclusions 
Thirteen laboratories subscribed for participation in the proficiency study macrolides in porcine tissue. 
Eleven laboratories managed to submit results for muscle. Ten of them were also able to report results 
for the kidney samples. Seven of the laboratories that reported results applied a validated method. The 
majority of labs applied the same method for muscle and kidney. Only one lab carried out an additional 
extraction for the kidney analysis using hexane. 
 
In this proficiency test three laboratories reported false negative results. These involved tylosin in 
muscle and tilmicosin in kidney. One of these labs also reported a false positive result: spiramycin in 
muscle. 
Table 10: Overview of the amount of satisfactory results for accuracy 
Matrix Compound 
No. laboratories 
that reported 
results 
No. of satisfactory
results for 
accuracy 
No. of questionable 
results for accuracy 
No. of 
unsatisfactory 
results for accuracy
Tylosin 10 8 2 0 
Josamycin 8 5 1 2 
Lincomycin 8 8 0 0 
Muscle 
Tulathromycin 5 5 0 0 
Tylosin 10 7 3 0 
Josamycin 7 5 1 1 Kidney 
Tilmicosin 6 6 0 0 
 
In all cases u > 0.3σp. This indicates that there is a severe variation among the laboratories. For several 
compounds the difference between the lowest and the highest reported value is a factor 5. As a result of 
this variation 6 of the 11 laboratories obtained questionable or unsatisfactory results.  
 
Based on the results of this proficiency study it is concluded that: 
• Although regulations for most macrolides are established before 2005, many laboratories do not 
have a validated and accreditated method for the analysis of all relevant macrolides.  
• For all compounds in both matrices the variation among the laboratories is severe. 
• For tylosin and josamycin more effort is needed for an accurate and more precise quantification of 
macrolides in porcine muscle. The elimination of ion suppression and the use of a well 
characterized tylosin reference standard could be important issues. 
• In general, more effort is needed to control food safety within Europe with respect to the occurrence 
of macrolide residues. 
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Annex 1 Codification of the samples 
Sample set Material M-A* Material M-B* Material K-A* Material K-B* 
1 109 031 077 008 
  069   
2 057 050 039 035 
  084   
3 079 066 031 047 
  104   
4 052 047 054 056 
  091   
5 072 060 015 028 
  099   
6 115 095 004 057 
  103   
7 114 005 016 044 
  094   
8 088 018 011 079 
  026   
9 020 013 098 034 
  107   
10 043 042 070 055 
  076   
11 062 006 012 066 
  038   
12 102 014 068 082 
  063   
13 100 068 076 027 
  101   
14 040 046 019 032 
  097   
15 093 070 083 042 
  092   
16 022 048 078 010 
  105   
17 067 055 071 075 
  081   
18 117 051 002 087 
  087   
19 023 064 009 089 
  078   
20 090 037 006 001 
  098   
* all muscle sample codes start with MACRO/2008/MUSCLE/ and the kidney sample codes with 
MACRO/2008/KIDNEY/ 
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Annex 2a Statistical evaluation of homogeneity data of material 
M-B for tylosin 
 Tylosin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 44.9 48.5 
2 50.8 59.0 
3 50.7 56.9 
4 62.3 58.0 
5 61.8 50.0 
6 52.9 51.2 
7 49.2 62.0 
8 54.5 49.7 
9 52.3 42.9 
10 46.9 47.5 
Grand mean 52.6 
Cochran’s test   
C 0.297 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 11.57  
sx 4.38 
sw 5.25 
ss 2.32 
Critical = 0.3 Hσ  3.47 
ss < critical? ACCEPTED 
 
No tilmicosin, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and valnemulin 
were detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2b Statistical evaluation of homogeneity data of material 
M-B for josamycin 
 Josamycin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 223 225 
2 224 269 
3 261 256 
4 281 268 
5 274 213 
6 242 229 
7 251 263 
8 253 261 
9 237 231 
10 227 220 
Grand mean 245 
Cochran’s test   
C 0.581 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 48.5  
sx 16.7 
sw 17.9 
ss 10.8 
Critical = 0.3 Hσ  14.6 
ss < critical? ACCEPTED 
 
No tilmicosin, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and valnemulin 
were detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2c Statistical evaluation of homogeneity data of material 
M-B for lincomycin 
 Lincomycin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 144 101 
2 136 137 
3 141 138 
4 151 138 
5 145 137 
6 162 156 
7 162 157 
8 162 153 
9 161 156 
10 151 110 
Grand mean 145 
Cochran’s test   
C 0.481 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 31.0 
sx 13.2 
sw 14.0 
ss 8.78 
Critical = 0.3 Hσ  9.30 
ss < critical? ACCEPTED 
 
No tilmicosin, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and valnemulin 
were detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2d Statistical evaluation of homogeneity data of material 
K-B for tylosin 
 Tylosin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 73.9 54.3 
2 54.4 55.0 
3 61.2 71.9 
4 71.9 70.3 
5* 74.5 65.5 
6 80.2 74.7 
7 77.4 59.3 
8 69.9 60.1 
9 59.6 87.0 
10 73.6 73.8 
Grand mean 68.4 
Cochran’s test   
C 0.420 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 15.1 
sx 6.38 
sw 9.46 
ss 0 
Critical = 0.3 Hσ  4.52 
ss < critical? ACCEPTED 
 
No lincomycin, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and 
valnemulin were detected in the samples.  
  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2e Statistical evaluation of homogeneity data of material 
K-B for josamycin 
 Josamycin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 284 180 
2 192 192 
3 191 254 
4 264 255 
5* 301 238 
6 293 259 
7 258 185 
8 237 226 
9 194 295 
10 289 258 
Grand mean 242 
Cochran’s test   
C 0.299 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  
Horwitz: 48.0 
sx 27.3 
sw 42.9 
ss 0 
Critical = 0.3 Hσ  
14.4 
ss < critical? ACCEPTED 
 
No lincomycin, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and 
valnemulin were detected in the samples.  
  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2f Statistical evaluation of homogeneity data of material 
K-B for tilmicosin 
 Tilmicosin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 38.4 23.9 
2 23.9 23.6 
3 25.3 28.7 
4 29.6 28.4 
5* 30.3 39.8 
6 39.3 28.8 
7 40.6 27.3 
8 30.6 27.1 
9 27.9 41.4 
10 33.1 29.8 
Grand mean 30.9 
Cochran’s test   
C 0.259 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  
Horwitz: 6.8 
sx 3.7 
sw 6.4 
ss 0 
Critical = 0.3 Hσ  
2.0 
ss < critical? ACCEPTED 
 
No lincomycin, aivlosin, erythromycin, gamithromycin, pirlimycin, tiamulin, spiramycin and 
valnemulin were detected in the samples.  
  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 7 Overview of false positive and false negative results 
False positive results 
Lab code Sample code Material Analyte found Replicate 1  
(µg/kg) 
Replicate 2  
(µg/kg) 
Lab 12 MACRO/2008/KIDNEY/068 K-A Spiramycin 192.5 192.7 
Lab 12 MACRO/2008/KIDNEY/082 K-B Spiramycin 86.7 90.7 
 
 
False negative results 
Lab code Sample code Material Analyte LoD (µg/kg) 
Lab 4 MACRO/2008/KIDNEY/056 Tilmicosin K-B 8 
Lab 8 MACRO/2008/KIDNEY/079 Tilmicosin K-B NM 
Lab 12 MACRO/2008/MUSCLE/014 Tylosin M-B 3 
Lab 12 MACRO/2008/MUSCLE/063 Tylosin M-B 3 
NM: Not mentioned 
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Annex 8a Results for the analysis of tylosin in muscle 
Tylosin 
Assigned value: 38.3 µg/kg 
Uncertainty of assigned value: 4.3 µg/kg 
Target standard deviation (Horwitz, Thompson):  8.4 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average sr sW z'a-score 
1 27 28 28 31 28,5 1,29 1,68 -1,04 
2 45 64 60 62 57,8 7,80 7,80 2,06 
3 30 31 35 36 33,0 0,58 3,56 -0,56 
4 33 28 25 32 29,5 3,51 3,51 -0,93 
5 24,3 24,0 29,1 25,1 25,6 1,64 2,39 -1,34 
6 41,2 40,2 32,3 37,5 37,8 2,16 4,38 -0,06 
7 25 27 24 26 25,5 1,15 1,15 -1,36 
8 76 62 41 56 58,8 8,38 15,66 2,16 
9 44,5 41,1 43,9 41,7 42,8 1,65 1,65 0,47 
13 59,1 55,4 59,7 75,4 62,4 6,59 8,64 2,55 
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Annex 8a continued Results for the analysis of tylosin in 
muscle 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-sc 
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Annex 8b Results for the analysis of tylosin in kidney 
Tylosin 
Assigned value: 66.7 µg/kg 
Uncertainty of assigned value: 11.5 µg/kg 
Target standard deviation (Horwitz, Thompson):  14.7 µg/kg 
Code Replicate 1 Replicate 2 Average za-score 
1 68 56 62,0 -0,25 
3 57 61 59,0 -0,41 
4 36 23 29,5 -1,99 
5 83,7 74,6 79,2 0,67 
6 30,1 38,2 34,2 -1,74 
7 41 36 38,5 -1,51 
8 75 121 98,0 1,68 
9 128 112 120,0 2,86 
12 109,4 113,5 111,5 2,40 
13 42 44,5 43,3 -1,26 
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Annex 8b continued Results for the analysis of tylosin in 
kidney 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-score               
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Annex 9a  Results for the analysis of josamycin in muscle 
Josamycin 
Assigned value: 197 µg/kg 
Uncertainty of assigned value: 41 µg/kg 
Target standard deviation (Horwitz, Thompson):  40 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average sr sW z'a-score 
1 112 113 112 117 113,5 2,08 2,08 -1,45 
2 238 281 274 307 275 22,13 26,93 1,37 
5 123,5 117,8 121,3 120,6 120,8 2,34 2,34 -1,33 
6 237 224 190 226 219,3 15,63 19,37 0,40 
7 121 122 119 117 119,8 0,91 2,56 -1,34 
8 434 380 492 437 435,8 31,47 46,35 4,18 
12 76,1 81,5 74,6 88,3 80,1 6,01 6,01 -2,04* 
13 371 331 320 524 386,5 84,87 84,87 3,32 
* Due to the consequential instability found this result is not suited for evaluation purposes. 
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Annex 9a continued Results for the analysis of josamycin in 
muscle 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-score               
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Annex 9b Results for the analysis of josamycin in kidney 
Josamycin 
Assigned value: 177 µg/kg 
Uncertainty of assigned value: 24 µg/kg 
Target standard deviation (Horwitz, Thompson):  37 µg/kg 
Code Replicate 1 Replicate 2 Average z'a-score 
1 181 161 171,0 -0,13 
5 151,8 137,4 144,6 -0,72 
6 159 174 166,5 -0,23 
7 121 122 121,5 -1,25 
8 372 441 406,5 5,22 
12 124,3 123,6 124,0 -1,19 
13 259 283 271,0 2,14 
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Annex 9b continued Results for the analysis of josamycin in 
kidney 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-score               
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Annex 10 Results for the analysis of lincomycin in muscle 
Lincomycin 
Assigned value: 120 µg/kg 
Uncertainty of assigned value: 11 µg/kg 
Target standard deviation (Horwitz, Thompson):  26 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average sr sW z'a-score 
1 88 90 100 108 96,5 3,37 10,87 -0,82 
2 158 160 147 160 156,3 5,37 5,44 1,25 
4 93 80 70 68 77,8 5,37 12,94 -1,48 
5 103,7 125,0 100,9 100,9 107,6 8,70 11,33 -0,44 
6 130 147 125 139 135,3 8,99 8,99 0,52 
7 104 105 101 103 103,3 0,91 1,88 -0,59 
12 124,1 134,6 139,5 140,6 134,7 4,31 8,16 0,50 
13 149,1 127 117 208 150,3 38,23 38,23 1,05 
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Annex 10 continued Results for the analysis of lincomycin in 
muscle 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-score               
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Annex 11 Results for the analysis of tulathromycin in muscle 
Tulathromycin 
Assigned value: 217 µg/kg 
Uncertainty of assigned value: 42 µg/kg 
Target standard deviation (Horwitz, Thompson):  43 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average sr sW z'a-score 
1 126 127 108 105 116,5 1,29 14,17 -1,65 
5 303,1 311,4 304,4 319,7 309,7 7,11 7,11 1,52 
6 159 224 188 243 203,5 34,76 34,76 -0,22 
9 173 163 145 175 164,0 12,91 12,91 -0,87 
13 276 250 235 408 292,3 71,42 71,42 1,23 
These results are not suited for evaluation purposes, but for information only.
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Annex 11 continued Results for the analysis of tulathromycin 
in muscle 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-score               
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Annex 12 Results for the analysis of tilmicosin in kidney 
Tilmicosin 
Assigned value: 35.2 µg/kg 
Uncertainty of assigned value: 3.5 µg/kg 
Target standard deviation (Horwitz, Thompson):  7.7 µg/kg 
Code Replicate 1 Replicate 2 Average z'a-score 
1 28   28,0 -0.85 
5 42.3 43.6 43.0 0.91 
6 42,6 42,0 42,3 0.84 
7 38 36 37,0 0.21 
12 25,0 22,8 23,9 -1.33 
13 36,8 35,9 36,4 0.14 
 RIKILT Report 2009.003 55
Annex 12 continued Results for the analysis of tilmicosin in 
kidney 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z'a-score               
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